Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2001

View Archived Issues

Inspire reports progress for two ophthalmic products at ARVO

Cell Genesys discusses highlights for the first quarter of 2001

ARVO 2001 presentations underline promise of squalamine in angiogenic eye diseases

Merger of BioChem Pharma and Shire to close this week

Ajinomoto's novel nucleoside analogue exerts therapeutically useful antiherpesvirus activity

Topical dapsone to be studied for new indication: atopic dermatitis

MGI's lead acylfulvene advances to phase II for refractory sarcoma

Phase I/II results reported for ADA in patients with advanced AIDS

BPI-derived compounds show promise for Rx of pathological retinal neovascularization

TLK-16998: a nonpeptide IR sensitizer effective in mouse models of type 2 diabetes

Enzon begins patient treatment in phase I trial of PEG-paclitaxel

U. of Maryland prepared to begin clinical testing of Multikine for cervical cancer

Potency of several retinoids assessed in bladder cancer cell lines

Lilly's duloxetine reduces symptoms of depression in clinical trials

Abbott presents novel cinnamide-based LFA-1/ICAM-1 antagonist with improved PK properties

Aventis warns of potential liver injury on Arava

Orally active Raf kinase inhibitor from Onyx/Bayer in phase I clinical trials

Avant's oral cholera vaccine shows safety and efficacy in phase IIb trial

Four Amgen products under regulatory review

Large number of D4 antagonists synthesized at Aventis

Eisai presents new acetylcholinesterase-inhibitory piperidines

New series from Ajinomoto with utility in inflammation, cancer, etc.

SB-263831 and related compounds act as caspase inhibitors

Human papillomavirus vaccine patented by Active Biotech

Metastasis-associated antigen discovered at German center

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...